Full Press Release Details
WALTHAM, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:
Event: Guggenheim 2ndAnnual Healthcare Innovation Conference - BostonDate:Monday, November 10, 2025Fireside Time:10:00 am ET
Event: Stifel 2025 Healthcare Conference – New YorkDate:Tuesday, November 11, 2025Fireside Time:8:40 am ET
Event: Jefferies Global Healthcare Conference - LondonDate:Wednesday, November 19, 2025Fireside Time:8:00 am GMT
Live audio webcasts and replays of these events will be available on the Spyre investor events website athttps://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, visit Spyre's website at www.spyre.com.